Results 61 to 70 of about 52,042 (217)

Triple Negative Breast Cancer - Review of Current and Emerging Therapeutic Strategies [PDF]

, 2016
Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically ...
Ballinger, Tarah, Kremer, Jill, Miller, Kathy   +2 more
core   +1 more source

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Journal for ImmunoTherapy of Cancer, 2019
Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells.
Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens   +9 more
doaj   +1 more source

Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies

Frontiers in Oncology, 2019
Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC).
Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, Zi-xian Wang   +3 more
doaj   +1 more source

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis [PDF]

, 2022
Xiaoyan Liu, Yitian Lang, Qingqing Chai, Yan Lin, Yahui Liao, Yi Zhun Zhu   +5 more
openalex   +1 more source

Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature [PDF]

, 2019
Immune checkpoint inhibitors are used to treat numerous malignancies but may be associated with severe adverse events. Bullous dermatoses, chiefly bullous pemphigoid (BP), are potentially progressive adverse events that cause blistering skin lesions and ...
Choi, Jennifer N, Kosche, Cory, Owen, Joshua L, Sadowsky, Lauren M   +3 more
core  

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]

, 2018
The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E., Duruisseaux, M., Fernández Fernández, Agustín, Fernández Fraga, Mario, Martínez Cardús, A.   +4 more
core   +1 more source

First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China

Chinese Medical Journal, 2019
. Background:. IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in
Ling-Yu Li, Hong Wang, Xiao Chen, Wen-Qian Li, Jiu-Wei Cui, Li-Min Chen   +5 more
doaj   +1 more source

Checkpoint inhibitors: What gastroenterologists need to know. [PDF]

, 2018
Checkpoint inhibitors are increasingly being used in clinical practice. They can cause various gastrointestinal, hepatic and pancreatic side effects. As these side effects can be serious, appropriate management is essential.
Ahmed, Monjur
core   +1 more source

A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: an application for bladder cancer treatment [PDF]

, 2016
Stealth pH-responsive liposomes for the delivery of therapeutic proteins to the bladder epithelium were prepared using methoxy-poly(ethylene glycol)5kDa-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG5kDa-DSPE) and stearoyl-poly(ethylene glycol ...
Balasso, Anna, Codolo, Gaia, DE BERNARD, Marina, Fassan, Matteo, Malfanti, Alessio, Munari, Fabio, Rugge, Massimo, Salmaso, Stefano, Vila Caballer, Marian   +8 more
core   +1 more source